SUKL to communicate with drug manufacturers by means of public announcements

2010-01-08

Since January 2010 all information on administrative procedures pertaining to the establishment of, or changes to, a maximum manufacturer’s price for a given medicine in the Czech Republic, along with its reimbursement levels, will not be delivered individually to the manufacturer by post, but will be published on the SUKL website in the form of a public notice, based on the new mode of communication which the Czech State Institute for Drug Control (SUKL) has stipulated for drug manufacturers and marketing authorisation holders. Remote access to public notices will be available via a specially created section of the SUKL website. The notice will be available on the website for 15 days, and after this period it is to be considered by the SUKL as having been delivered.
Through its website the SUKL offers access to all administrative decisions pertaining to the establishment of, or changes to, maximum drug prices and reimbursement levels. They can be accessed by means of the website after a certified, electronically signed application has been submitted.